Old Web
English
Sign In
Acemap
>
authorDetail
>
Gabrielle Leclercq
Gabrielle Leclercq
Hoffmann-La Roche
Cancer research
Cytokine
Dasatinib
cell killing
T cell
3
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
P09.01 The use of FDA approved JAK, mTOR and Src inhibitors to regulate T cell-bispecific antibody-induced cytokine release while not preventing T cell cytotoxicity
2021
Journal for ImmunoTherapy of Cancer
Gabrielle Leclercq
Helene Haegel
Anneliese Schneider
Anna Maria Giusti
Vesna Pulko
A Toso
T Zimmermann
L Green
Nathalie Steinhoff
Johannes Sam
Marina Bacac
Pablo Umana
Christian Klein
Show All
Source
Cite
Save
Citations (0)
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
2021
Journal for ImmunoTherapy of Cancer
Gabrielle Leclercq
Helene Haegel
Anneliese Schneider
Anna Maria Giusti
Estelle Marrer-Berger
Christophe Boetsch
Antje-Christine Walz
Vesna Pulko
Johannes Sam
John Challier
Cristiano Ferlini
Alex Odermatt
Pablo Umana
Marina Bacac
Christian Klein
Show All
Source
Cite
Save
Citations (2)
653 Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release
2020
Journal for ImmunoTherapy of Cancer
Gabrielle Leclercq
Helene Haegel
Anneliese Schneider
Estelle Marrer-Berger
Antje Walz
Christophe Boetsch
Vesna Pulko
Cristiano Ferlini
Christian Klein
Show All
Source
Cite
Save
Citations (0)
1